Literature DB >> 20687162

Sample size determination in clinical trials with multiple co-primary binary endpoints.

Takashi Sozu1, Tomoyuki Sugimoto, Toshimitsu Hamasaki.   

Abstract

Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different. 2010 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 20687162     DOI: 10.1002/sim.3972

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  14 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Authors:  Toshimitsu Hamasaki; Koko Asakura; Scott R Evans; Tomoyuki Sugimoto; Takashi Sozu
Journal:  Stat Biopharm Res       Date:  2015       Impact factor: 1.452

3.  Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.

Authors:  Feng Gao; Guoqiao Wang; Jingqin Luo; Jingxia Liu; Ling Chen; Chengjie Xiong
Journal:  Stat Biopharm Res       Date:  2019-04-18       Impact factor: 1.452

4.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

5.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

Review 6.  Registration and design alterations of clinical trials in critical care: a cross-sectional observational study.

Authors:  Vijay Anand; Damon C Scales; Christopher S Parshuram; Brian P Kavanagh
Journal:  Intensive Care Med       Date:  2014-04-16       Impact factor: 17.440

Review 7.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

8.  Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.

Authors:  Yuki Ando; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Tomoyuki Sugimoto; Takashi Sozu; Yuko Ohno
Journal:  Stat Biopharm Res       Date:  2015-06-24       Impact factor: 1.452

9.  Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Authors:  Toshimitsu Hamasaki; Tomoyuki Sugimoto; Scott Evans; Takashi Sozu
Journal:  Pharm Stat       Date:  2012-10-19       Impact factor: 1.894

10.  A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.

Authors:  Grace Montepiedra; Ritesh Ramchandani; Sachiko Miyahara; Soyeon Kim
Journal:  Stat Med       Date:  2020-10-26       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.